5.90
+0.005(+0.08%)
Currency In USD
| Previous Close | 5.9 |
| Open | 5.95 |
| Day High | 6.05 |
| Day Low | 5.84 |
| 52-Week High | 7.89 |
| 52-Week Low | 2.8 |
| Volume | 9,851 |
| Average Volume | 22,330 |
| Market Cap | 24.48M |
| PE | 3.49 |
| EPS | 1.69 |
| Moving Average 50 Days | 5.83 |
| Moving Average 200 Days | 5.62 |
| Change | 0.01 |
If you invested $1000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, it would be worth $0.05 as of July 16, 2025 at a share price of $5.9. Whereas If you bought $1000 worth of Tenax Therapeutics, Inc. (TENX) shares 5 years ago, it would be worth $3.45 as of July 16, 2025 at a share price of $5.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Mar 31, 2025 12:00 PM GMT
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary ther
Tenax Therapeutics Announces $25 Million Private Placement
GlobeNewswire Inc.
Mar 05, 2025 1:47 PM GMT
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary ther
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
GlobeNewswire Inc.
Mar 05, 2025 1:42 PM GMT
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with First Patient Expected to be Enroll